KRYSTAL-1: Multiple Cohort Study of Adagrasib Monotherapy or Combinations for Patients With KRAS G12C Mutant Solid Tumors
Condition: Solid Tumors
Sponsor: Mirati Therapeutics Inc.
Full Title
849-001: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Study Treatment
Oral KRAS G12C inhibitor adagrasib alone or in combination with pembrolizumab or cetuximab
Eligibility/Info
Phase 2, Cohort D: Advanced or metastatic KRAS G12C mutant solid tumor (other than NSCLC, CRC, PDAC) without available standard of care treatment options
Phase 1 Sub-Study: Advanced or metastatic KRAS G12C inhibitor naïve KRAS G12C mutant non-small cell lung cancer without available standard of care treatment options
Phase 1 Sub-Study: Advanced or metastatic KRAS G12C inhibitor naïve KRAS G12C mutant pancreatic ductal adenocarcinoma without available standard of care treatment options
Phase 1b: KRAS G12C mutant NSCLC with brain metastasis
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.